A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Recruiting · NCT06994676 · Registry updated 2026-03-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-03-16 | NCT06994676 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Crossbow Therapeutics, Inc. | 2 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope | Duarte | United States | 238 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| Northwestern Medicine | Chicago | United States | 36 |
| Sarah Cannon Cancer Institute | Nashville | United States | 3 |
| Stanford Medical Center | Palo Alto | United States | 2 |
| Thomas Jefferson University Hospital | Philadelphia | United States | 271 |
| Vanderbilt University Medical Center | Nashville | United States | 427 |
| Washington University in St. Louis | St Louis | United States | 79 |